Medical Science
| Open Access |
DOI: Therapy After Percutaneous Coronary Intervention in Chronic Coronary Disease: A Practical Review for Internal Medicine and Interventional Cardiology
Akramov Bekhzod Bakhromjon o'gli , Assistant, Department of Internal Diseases, Nephrology and Hemodialysis, Tashkent State Medical University, Tashkent, Uzbekistan Research Applicant at The Republican Specialized Scientific and Practical Medical Center of Nephrology and Kidney Transplantation, UzbekistanAbstract
Percutaneous coronary intervention (PCI) is a central procedure in modern cardiology, but the long-term prognosis of patients with chronic coronary disease is determined not only by mechanical revascularization. Durable benefit after PCI depends on the systematic control of atherosclerotic risk, correct selection and duration of antiplatelet therapy, intensive lipid lowering, blood pressure and glycemic optimization, antianginal treatment, rehabilitation, and patient adherence. Recent European and American recommendations increasingly frame coronary artery disease as a chronic, multidisciplinary condition that requires coordinated follow-up after the catheterization laboratory. This review summarizes current evidence and provides a practical outpatient algorithm for therapy departments and interventional cardiology services managing adults after PCI. The article focuses on five clinically important domains: antithrombotic therapy, lipid-lowering escalation, antianginal and hemodynamic treatment, cardiometabolic risk modification, and structured post-discharge follow-up. A stepwise checklist is proposed for visits at 7-14 days, 1-3 months, and 6-12 months after PCI. The practical aim is to reduce fragmentation of care, improve documentation of treatment goals, and help physicians translate guideline recommendations into everyday practice. The proposed approach is particularly relevant for patients with diabetes, hypertension, chronic kidney disease, obesity, previous myocardial infarction, multivessel coronary disease, and high bleeding risk, in whom a single uniform post-PCI prescription is insufficient.
Keywords
Chronic coronary disease, chronic coronary syndrome, percutaneous coronary intervention
References
Vrints C, Andreotti F, Koskinas KC, Rossello X, Adamo M, Ainslie J, et al. 2024 ESC Guidelines for the management of chronic coronary syndromes. European Heart Journal. 2024;45(36):3415-3537. doi:10.1093/eurheartj/ehae177.
Virani SS, Newby LK, Arnold SV, Bittner V, Brewer LC, Demeter SH, et al. 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the management of patients with chronic coronary disease. Circulation. 2023;148:e9-e119. doi:10.1161/CIR.0000000000001168.
Byrne RA, Rossello X, Coughlan JJ, Barbato E, Berry C, Chieffo A, et al. 2023 ESC Guidelines for the management of acute coronary syndromes. European Heart Journal. 2023;44:3720-3826.
Lawton JS, Tamis-Holland JE, Bangalore S, Bates ER, Beckie TM, Bischoff JM, et al. 2021 ACC/AHA/SCAI Guideline for coronary artery revascularization. Journal of the American College of Cardiology. 2022;79:e21-e129.
Knuuti J, Wijns W, Saraste A, Capodanno D, Barbato E, Funck-Brentano C, et al. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. European Heart Journal. 2020;41:407-477.
Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias. European Heart Journal. 2020;41:111-188.
Cannon CP, Blazing MA, Giugliano RP, McCagg A, White JA, Theroux P, et al. Ezetimibe added to statin therapy after acute coronary syndromes. New England Journal of Medicine. 2015;372:2387-2397.
Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy SA, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. New England Journal of Medicine. 2017;376:1713-1722.
Schwartz GG, Steg PG, Szarek M, Bhatt DL, Bittner VA, Diaz R, et al. Alirocumab and cardiovascular outcomes after acute coronary syndrome. New England Journal of Medicine. 2018;379:2097-2107.
Nissen SE, Lincoff AM, Brennan D, Ray KK, Mason D, Kastelein JJP, et al. Bempedoic acid and cardiovascular outcomes in statin-intolerant patients. New England Journal of Medicine. 2023;388:1353-1364.
Valgimigli M, Frigoli E, Heg D, Tijssen J, Juni P, Vranckx P, et al. Dual antiplatelet therapy after PCI in patients at high bleeding risk. New England Journal of Medicine. 2021;385:1643-1655.
Mehran R, Baber U, Sharma SK, Cohen DJ, Angiolillo DJ, Briguori C, et al. Ticagrelor with or without aspirin in high-risk patients after PCI. New England Journal of Medicine. 2019;381:2032-2042.
Bhatt DL, Steg PG, Mehta SR, Leiter LA, Simon T, Fox K, et al. Ticagrelor in patients with diabetes and stable coronary artery disease with a history of previous percutaneous coronary intervention. Circulation. 2019;140:1725-1735.
Bonaca MP, Bhatt DL, Cohen M, Steg PG, Storey RF, Jensen EC, et al. Long-term use of ticagrelor in patients with prior myocardial infarction. New England Journal of Medicine. 2015;372:1791-1800.
Yusuf S, Joseph P, Dans A, Gao P, Teo K, Xavier D, et al. Polypill with or without aspirin in persons without cardiovascular disease. New England Journal of Medicine. 2021;384:216-228.
Tardif JC, Kouz S, Waters DD, Bertrand OF, Diaz R, Maggioni AP, et al. Efficacy and safety of low-dose colchicine after myocardial infarction. New England Journal of Medicine. 2019;381:2497-2505.
Nidorf SM, Fiolet ATL, Mosterd A, Eikelboom JW, Schut A, Opstal TSJ, et al. Colchicine in patients with chronic coronary disease. New England Journal of Medicine. 2020;383:1838-1847.
Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. New England Journal of Medicine. 2015;373:2117-2128.
Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondu N, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. New England Journal of Medicine. 2017;377:644-657.
Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JFE, Nauck MA, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. New England Journal of Medicine. 2016;375:311-322.
Marso SP, Bain SC, Consoli A, Eliaschewitz FG, Jodar E, Leiter LA, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. New England Journal of Medicine. 2016;375:1834-1844.
Lincoff AM, Brown-Frandsen K, Colhoun HM, Deanfield J, Emerson SS, Esbjerg S, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes. New England Journal of Medicine. 2023;389:2221-2232.
Piepoli MF, Hoes AW, Agewall S, Albus C, Brotons C, Catapano AL, et al. European Guidelines on cardiovascular disease prevention in clinical practice. European Heart Journal. 2016;37:2315-2381.
Visseren FLJ, Mach F, Smulders YM, Carballo D, Koskinas KC, Back M, et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. European Heart Journal. 2021;42:3227-3337.
Anderson L, Oldridge N, Thompson DR, Zwisler AD, Rees K, Martin N, et al. Exercise-based cardiac rehabilitation for coronary heart disease. Journal of the American College of Cardiology. 2016;67:1-12.
Download and View Statistics
Copyright License
Copyright (c) 2026 Akramov Bekhzod Bakhromjon o'gli
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors retain the copyright of their manuscripts, and all Open Access articles are disseminated under the terms of the Creative Commons Attribution License 4.0 (CC-BY), which licenses unrestricted use, distribution, and reproduction in any medium, provided that the original work is appropriately cited. The use of general descriptive names, trade names, trademarks, and so forth in this publication, even if not specifically identified, does not imply that these names are not protected by the relevant laws and regulations.